• Philip C Robinson, Robert Terkeltaub, Michael H Pillinger, Binita Shah, Vangelis Karalis, Eleni Karatza, David Liew, Massimo Imazio, Jan H Cornel, Peter L Thompson, and Mark Nidorf.
• University of Queensland School of Clinical Medicine, Faculty of Medicine, Herston, Qld, Australia; Royal Brisbane & Women's Hospital, Metro North Hospital & Health Service, Herston, Qld, Australia. Electronic address: philip.robinson@uq.edu.au.
• Am. J. Med. 2022 Jan 1; 135 (1): 32-38.

AbstractOver the last decade, evidence has demonstrated that long-term, low-dose colchicine (0.5 mg daily) is effective for preventing gout flare and cardiovascular (CV) events in a wide range of patients. Given the potentially expanding use of colchicine in CV disease, we here review and update the biologic effects and safety of colchicine based on recent data gathered from bench and pharmacodynamic studies, clinical reports, controlled clinical trials, and meta-analyses, integrated with important studies over the last 50 years, to offer a consensus perspective by experts from multiple specialties familiar with colchicine's long-term use. We conclude that the clinical benefits of colchicine in gout and CV disease achieved at low dose do not sustain serum levels above the upper limit of safety when used in patients without advanced renal or liver disease or when used concomitantly with most medications. Further, data accrued over the last 50 years strongly suggest that the biologic effects of long-term colchicine do not increase the risk of cancer, sepsis, cytopenia, or myotoxicity.Copyright © 2021 Elsevier Inc. All rights reserved.

15 keywords...

hide…